Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Marcus Hompesch

Showing results (31-40 of 53) with videos related to

Pageof 6
Sort By:
Plos One|August 29, 2014
Pharmacodynamic effects of canagliflozin, a sodium glucose co-transporter 2 inhibitor, from a randomized study in patients with type 2 diabetesSue Sha, Damayanthi Devineni, Atalanta Ghosh, et al.
The Journal of Clinical Endocrinology and Metabolism|December 15, 2019
Sotagliflozin Decreases Postprandial Glucose and Insulin Concentrations by Delaying Intestinal Glucose AbsorptionDavid R Powell, Brian Zambrowicz, Linda Morrow, et al.
Journal of Diabetes|January 13, 2015
Steady state is reached within 2-3 days of once-daily administration of degludec, a basal insulin with an ultralong duration of actionTim Heise, Stefan Korsatko, Leszek Nosek, et al.
Journal of Diabetes Science and Technology|September 2, 2011
Evaluation of a novel continuous glucose measurement device in patients with diabetes mellitus across the glycemic rangeLinda Morrow, Marcus Hompesch, Ann M Tideman, et al.
Diabetes, Obesity & Metabolism|July 3, 2019
Body weight management and safety with efpeglenatide in adults without diabetes: A phase II randomized studyRichard E Pratley, Jahoon Kang, Michael E Trautmann, et al.
Diabetes|April 2, 2025
A Randomized-Controlled, Double-Masked Cross-Over Study of a GPR119 Agonist on Glucagon Counterregulation during Hypoglycemia in Type 1 DiabetesAnika Bilal, Anna Casu, Fanchao Yi, et al.
Diabetes Technology & Therapeutics|February 9, 2011
Continuous glucose monitoring using a novel glucose/galactose binding protein: results of a 12-hour feasibility study with the becton dickinson glucose/galactose binding protein sensorKevin Judge, Linda Morrow, Alexander G Lastovich, et al.
Diabetes Technology & Therapeutics|March 2, 2011
Intradermal microneedle delivery of insulin lispro achieves faster insulin absorption and insulin action than subcutaneous injectionRonald J Pettis, Barry Ginsberg, Laurence Hirsch, et al.
BMJ Open Diabetes Research & Care|January 19, 2022
Efficacy and safety of efpeglenatide in key patient subgroups from the BALANCE randomized trial, stratified by pre-diabetes status, BMI, and age at baselineRichard E Pratley, Stephan Jacob, Seungjae Baek, et al.
The Journal of Clinical Endocrinology and Metabolism|December 24, 2025
Sustained Action of Imapextide, a Glucagon-Like Peptide-1 Receptor Antagonist, in Healthy VolunteersElisa Fabbrini, Anastasiya Koshkina, Michael Hackett, et al.
Pageof 6

Showing results (31-40 of 53) with videos related to

Sort By:
Pageof 6
Plos One|August 29, 2014
Pharmacodynamic effects of canagliflozin, a sodium glucose co-transporter 2 inhibitor, from a randomized study in patients with type 2 diabetesSue Sha, Damayanthi Devineni, Atalanta Ghosh, et al.
The Journal of Clinical Endocrinology and Metabolism|December 15, 2019
Sotagliflozin Decreases Postprandial Glucose and Insulin Concentrations by Delaying Intestinal Glucose AbsorptionDavid R Powell, Brian Zambrowicz, Linda Morrow, et al.
Journal of Diabetes|January 13, 2015
Steady state is reached within 2-3 days of once-daily administration of degludec, a basal insulin with an ultralong duration of actionTim Heise, Stefan Korsatko, Leszek Nosek, et al.
Journal of Diabetes Science and Technology|September 2, 2011
Evaluation of a novel continuous glucose measurement device in patients with diabetes mellitus across the glycemic rangeLinda Morrow, Marcus Hompesch, Ann M Tideman, et al.
Diabetes, Obesity & Metabolism|July 3, 2019
Body weight management and safety with efpeglenatide in adults without diabetes: A phase II randomized studyRichard E Pratley, Jahoon Kang, Michael E Trautmann, et al.
Diabetes|April 2, 2025
A Randomized-Controlled, Double-Masked Cross-Over Study of a GPR119 Agonist on Glucagon Counterregulation during Hypoglycemia in Type 1 DiabetesAnika Bilal, Anna Casu, Fanchao Yi, et al.
Diabetes Technology & Therapeutics|February 9, 2011
Continuous glucose monitoring using a novel glucose/galactose binding protein: results of a 12-hour feasibility study with the becton dickinson glucose/galactose binding protein sensorKevin Judge, Linda Morrow, Alexander G Lastovich, et al.
Diabetes Technology & Therapeutics|March 2, 2011
Intradermal microneedle delivery of insulin lispro achieves faster insulin absorption and insulin action than subcutaneous injectionRonald J Pettis, Barry Ginsberg, Laurence Hirsch, et al.
BMJ Open Diabetes Research & Care|January 19, 2022
Efficacy and safety of efpeglenatide in key patient subgroups from the BALANCE randomized trial, stratified by pre-diabetes status, BMI, and age at baselineRichard E Pratley, Stephan Jacob, Seungjae Baek, et al.
The Journal of Clinical Endocrinology and Metabolism|December 24, 2025
Sustained Action of Imapextide, a Glucagon-Like Peptide-1 Receptor Antagonist, in Healthy VolunteersElisa Fabbrini, Anastasiya Koshkina, Michael Hackett, et al.
Pageof 6